{"entity":{"id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","aka":[],"tldr":"A phase 1/2 trial of Fludarabine, Cyclophosphamide in hepatocellular carcinoma, run by Beijing Biotech, now recruiting.","summary":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC is a phase 1/2 interventional study registered as NCT07500220 by Beijing Biotech, with 30 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07500220","url":"https://clinicaltrials.gov/study/NCT07500220"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07500220","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose-Escalation and Dose-Expansion Study of Allogeneic Dual-Target GPC3/B7-H3 (CD276) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Relapsed/Refractory, or Metastatic Hepatocellular Carcinoma","sponsor":"Beijing Biotech","enrolled":30,"outcomes":[]},"route":"/trials/nct07500220/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}